作者: Miklós Krepuska , Péter Sótonyi , Csaba Csobay-Novák , Zoltán Szeberin , István Hartyánszky
DOI: 10.1016/J.REGPEP.2011.01.007
关键词:
摘要: Abstract Background Clinical studies are limited regarding the role of human nociceptin/orphanin FQ (N/OFQ) in ischemic cardiovascular diseases, which still number one cause death developed world. The aim our study was to measure plasma levels N/OFQ patients with chronic diseases a pilot study. Methods and results Our population consisted 22 presenting symptoms stable angina pectoris (SAP): 12 severe Canadian Cardiovascular Society (CCS) III–IV functional class, 10 milder SAP (CCS II–III). were also enrolled peripheral artery disease (9 intermittent claudication; 3 rest pain gangrene). Patients asked avoid any exertion or given analgetics for their pain. had no episodes chest limb 1 week before fasting blood samples taken measured by radioimmunoassay. 14 healthy subjects without cardiac risk factors served as control group. Conclusions significantly lower patient groups vs. (p